Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033646 | 1.00 | NPSR1 (0.48) | NPSR1ALDH1A1KMT2ALMNACYP26A1 | |
| SCHEMBL5033647 | 0.80 | LMNA (0.45) | NPSR1ALDH1A1KMT2ALMNACYP26A1 | |
| SCHEMBL5033745 | 0.69 | LMNA (0.39) | ALDH1A1KMT2ALMNACYP26A1CCR2 | |
| SCHEMBL5033633 | 0.67 | CCR2 (0.43) | ALDH1A1KMT2ALMNACYP26A1CCR2 | |
| SCHEMBL5033628 | 0.67 | CCR2 (0.43) | ALDH1A1KMT2ALMNACYP26A1CCR2 | |
| SCHEMBL13753347 | 0.65 | LMNA (0.58) | ALDH1A1KMT2ALMNACYP26A1RAB9A | |
| SCHEMBL13792985 | 0.62 | MCHR1 (0.67) | LMNA | |
| SCHEMBL9782938 | 0.62 | G6PC1 (0.47) | ALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL18062678 | 0.62 | GRIN2B (0.47) | RAB9ANPC1 | |
| SCHEMBL27162493 | 0.62 | GRIN2B (0.47) | RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | NPSR1 303/4885ALDH1A1 827/4885KMT2A 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.